Martinelli G et al. Proc ASH 2015;Abstract 679.

Slides:



Advertisements
Similar presentations
Palumbo A et al. Proc ASH 2013;Abstract 536.
Advertisements

Brown JR et al. Proc ASH 2013;Abstract 523.
Paz-Ares LG et al. Proc ASCO 2011;Abstract CRA7510.
Wilson WH et al. Proc ASH 2012;Abstract 686.
Goede V et al. Proc ASCO 2013;Abstract 7004.
Palumbo A et al. Proc ASH 2012;Abstract 446.
Results of a Phase II Trial of Brentuximab Vedotin as First Line Salvage Therapy in Relapsed/Refractory HL Prior to AHCT Chen RW et al. Proc ASH 2014;Abstract.
Single-Agent Lenalidomide in Patients with Relapsed/Refractory Mantle Cell Lymphoma Following Bortezomib: Efficacy, Safety and Pharmacokinetics from the.
Treatment with Bendamustine- Bortezomib-Dexamethasone in Relapsed/Refractory Multiple Myeloma Shows Significant Activity and Is Well Tolerated Ludwig H.
Interim Results of an International, Multicenter, Phase 2 Study of Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765), in Relapsed or Refractory.
Ponatinib as Initial Therapy for Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Cortes JE et al. Proc ASH 2013;Abstract 1483.
A Phase 2 Study of Elotuzumab in Combination with Lenalidomide and Low-Dose Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: Updated.
Viardot A et al. Proc ASH 2014;Abstract 4460.
Ibrutinib in Combination with Bendamustine and Rituximab Is Active and Tolerable in Patients with Relapsed/Refractory CLL/SLL: Final Results of a Phase.
A Phase II Study with Carfilzomib, Cyclophosphamide and Dexamethasone (CCd) for Newly Diagnosed Multiple Myeloma Bringhen S et al. Proc ASH 2013;Abstract.
Ibrutinib, Single Agent or in Combination with Dexamethasone, in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (MM): Preliminary Phase.
Ruan J et al. Proc ASH 2013;Abstract 247.
Epic: A Phase 3 Trial of Ponatinib Compared with Imatinib in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CP-CML) Lipton JH.
CD19-Targeted 19-28z CAR Modified Autologous T Cells Induce High Rates of Complete Remission and Durable Responses in Adult Patients with Relapsed, Refractory.
Improved Survival in Patients with First Relapsed or Refractory Acute Myeloid Leukemia (AML) Treated with Vosaroxin plus Cytarabine versus Placebo plus.
Head-to-Head Comparison of Obinutuzumab (GA101) plus Chlorambucil (Clb) versus Rituximab plus Clb in Patients with Chronic Lymphocytic Leukemia (CLL) and.
Results of a Randomized Phase 2 Study of PD , a Cyclin ‐ Dependent Kinase (CDK) 4/6 Inhibitor, in Combination with Letrozole vs Letrozole Alone.
Initial Findings from the PACE Trial: A Pivotal Phase 2 Study of Ponatinib in Patients with CML and Ph+ ALL Resistant or Intolerant to Dasatinib or Nilotinib,
Switching to Nilotinib in Patients with Chronic Myeloid Leukemia in Chronic Phase with Suboptimal Cytogenetic Response on Imatinib: Results from the LASOR.
A Pivotal Phase 2 Trial of Ponatinib in Patients with CML and Ph+ ALL Resistant or Intolerant to Dasatinib or Nilotinib, or with the T315I BCR ‐ ABL Mutation:
A Phase II Study of Lenalidomide for Previously Untreated Deletion (del) 5q Acute Myeloid Leukemia (AML) Patients Age 60 or Older Who Are Not Candidates.
A Multi-Center Phase I/II Trial of Carfilzomib and Pomalidomide with Dexamethasone (Car-Pom-d) in Patients with Relapsed/Refractory Multiple Myeloma Shah.
Ibrutinib in Combination with Rituximab (iR) Is Well Tolerated and Induces a High Rate of Durable Remissions in Patients with High- Risk Chronic Lymphocytic.
Bosutinib as Therapy for Chronic Phase Chronic Myeloid Leukemia Following Resistance or Intolerance to Imatinib: 36-Month Minimum Follow-Up Update Cortes.
Phase II Multicenter Study of Single-Agent Lenalidomide in Subjects with Mantle Cell Lymphoma Who Relapsed or Progressed After or Were Refractory to Bortezomib:
Kantarjian HM et al. Proc ASH 2012;Abstract Long-Term Follow-Up of Ongoing Patients in 2 Studies of Omacetaxine Mepesuccinate for Chronic Myeloid.
Pomalidomide + Low-Dose Dexamethasone (POM + LoDex) vs High-Dose Dexamethasone (HiDex) in Relapsed/Refractory Multiple Myeloma (RRMM): MM-003 Analysis.
1 Oliva EN et al Proc ASH 2015;Abstract 91.
ELIANA: CTL019 Shows High CR Rate in Pediatric/Young Adult Patients With Relapsed/Refractory B-Cell ALL New Findings in Hematology: Independent Conference.
Moskowitz CH et al. Proc ASH 2015;Abstract 182.
Chen R et al. Proc ASH 2015;Abstract 518.
19-28z CAR T-Cell Efficacy and Toxicity in Adults With R/R B-Cell ALL
Final Results from a Phase 2 Study of Pracinostat in Combination with Azacitidine in Elderly Patients with Acute Myeloid Leukemia (AML)1   CC-486 (Oral.
1 Stone RM et al. Proc ASH 2015;Abstract 6.
Maury S et al. Proc ASH 2015;Abstract 1.
Blinatumomab After AlloHSCT in Patients With R/R B-Precursor ALL
Shustov AR et al. Proc ASH 2010;Abstract 961.
Soverini S et al. Proc ASH 2015;Abstract 346.
CCO Independent Conference Highlights
Nivolumab in Patients (Pts) with Relapsed or Refractory Classical Hodgkin Lymphoma (R/R cHL): Clinical Outcomes from Extended Follow-up of a Phase 1 Study.
IFM/DFCI 2009 Trial: Autologous Stem Cell Transplantation (ASCT) for Multiple Myeloma (MM) in the Era of New Drugs Phase III study of lenalidomide/bortezomib/dexamethasone.
Randomized, Open-Label Phase 1/2 Study of Pomalidomide Alone or in Combination with Low-Dose Dexamethasone in Patients with Relapsed and Refractory Multiple.
Ibrutinib plus Rituximab in Treatment-Naive Patients with Follicular Lymphoma: Results from a Multicenter, Phase 2 Study1 Phase I Study of Rituximab,
Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia
Early Molecular and Cytogenetic Response Predict for Better Outcomes in Untreated Patients with CML-CP — Comparison of 4 TKI Modalities (Standard- and.
Fujiwara H et al. Proc ASH 2015;Abstract 181.
Jabbour E et al. Proc ASH 2015;Abstract 83.
DeAngelo DJ et al. Proc ASH 2015;Abstract 80.
San Miguel JF et al. 1 Proc EHA 2013;Abstract S1151.
Goede V et al. Proc ASH 2014;Abstract 3327.
New Findings in Hematology: Independent Conference Coverage
Dimopoulos MA et al. Proc ASH 2012;Abstract LBA-6.
Joensuu H et al. Proc ASCO 2011;Abstract LBA1.
Cortes JE et al. Proc ASCO 2010;Abstract 6502.
Ferrajoli A et al. Proc ASH 2010;Abstract 1395.
Coiffier B et al. Proc ASH 2010;Abstract 857.
Faderl S et al. Proc ASCO 2011;Abstract 6503.
Seymour JF et al. Proc ASH 2013;Abstract 872.
Forero-Torres A et al. Proc ASH 2011;Abstract 3711.
Zaja F et al. Proc ASH 2010;Abstract 966.
Blinatumomab Versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia
Ahmadi T et al. Proc ASH 2011;Abstract 266.
Advani RH et al. Proc ASH 2011;Abstract 443.
1Kantarjian HM et al. Lancet Oncol 2011;12:
Leber B et al. Proc ASH 2013;Abstract 94.
Presentation transcript:

Martinelli G et al. Proc ASH 2015;Abstract 679. Complete Molecular and Hematologic Response in Adult Patients with Relapsed/Refractory (R/R) Philadelphia Chromosome-Positive B-Precursor Acute Lymphoblastic Leukemia (ALL) Following Treatment with Blinatumomab: Results from a Phase 2 Single-Arm, Multicenter Study (ALCANTARA) Martinelli G et al. Proc ASH 2015;Abstract 679.

ALCANTARA Trial: Blinatumomab in Relapsed/Refractory (R/R) Philadelphia Chromosome-Positive (Ph+) B-Cell Acute Lymphoblastic Leukemia (ALL) Phase II, single-arm, multicenter study of blinatumomab, an anti- CD19 targeted, bispecific T-cell engaging antibody construct N = 45 patients with Ph+ B-cell ALL Resistant to a second- or third-generation tyrosine kinase inhibitor (TKI): n = 44 Never exposed to a second- or third-generation TKI but resistant to imatinib: n = 1 Primary endpoint: Complete response (CR) or CR with partial hematologic recovery (CRh) CR/CRh (all patients): 16/45 (36%) T315I mutation: 4/10 (40%) ≥2 prior second-generation TKIs: 11/27 (41%) Prior ponatinib: 8/23 (35%) Age 18 to <55 years: 8/22 (36%); age ≥55 years: 8/23 (35%) Median overall survival (n = 45): 7.1 months Median recurrence-free survival (RFS) (n = 16): 6.7 months Martinelli G et al. Proc ASH 2015;Abstract 679.

ALCANTARA: Conclusions Adverse events were consistent with those previously reported with blinatumomab for R/R Ph-negative ALL: Cytokine release syndrome (n = 4, any grade), neurologic events (n = 21, any grade; n = 3, Grade 3)   Grade ≥3 treatment-emergent adverse events (n = 37) included febrile neutropenia (12), thrombocytopenia (10) and anemia (7) Single-agent blinatumomab demonstrates antileukemic activity in patients with Ph+ R/R ALL after failure of 2nd- or 3rd-generation TKI, with a CR/CRh rate of 36%. Hematologic and molecular responses were independent of mutational status, including the T315I mutation. For patients <55 and ≥55 years of age: Equivalent CR/CRh rates Equivalent median RFS (5.5 mo vs 6.7 mo) Among responders, 88% (14/16) achieved minimal residual disease- negative status. Martinelli G et al. Proc ASH 2015;Abstract 679.

Investigator Commentary: Results of a Phase II Trial of Blinatumomab in Adult Patients with R/R Ph+ B-Precursor ALL The bispecific antibody blinatumomab has been approved for use in R/R Philadelphia chromosome-negative ALL. This antibody, which physically brings T cells together with CD19-positive lymphoblasts, has been highly effective in both advanced-disease and minimal residual disease settings. Although blinatumomab is known to have activity in Ph+ B-cell ALL, this study shows the potential value of using it in R/R Ph+ disease, yielding a 36% CR/CRh rate. Interview with Richard M Stone, MD, February 16, 2016